


FIGURE 1A




FIGURE 1B



Total MDSC (n=5)
CD11b+CD33+HLA-DR-
NT
TLR4
TLR7
TLR9A
TLR9B
SD101
* p<0.05; ** p<0.01 compared with NT
# p<0.05 compared with SD101
& p=0.06 compared with SD101
mMDSC/gMDSC (n=5)
M/G-MDSC ratio
*** p<0.001; **** p<0.0001 compared with NT
% p< 0.01; ^ p<0.001 compared with SD101
M1 MACROPHAGES
(n=5)
MFI CD14+
* p<0.05; ** p<0.01 compared with NT
# p<0.05; % p<0.01; @ p<0.00001 compared with SD101
M2 MACROPHAGES
(n=5)
* p<0.05 compared with NT

FIGURE 2A




FIGURE 2B



MDSC*
(CD11b+Gr-1+, n=3)
Fold change CD11b+GR-1+ over NT
NT
TLR4
TLR7
TLR9A
TLR9B
SD101
** p<0.01; **** p<0.0001 compared with NT
MACROPHAGES
(11b+F4/80+,
n=3)
Fold change CD11b+F4/80+ over NT
*** p<0.001; ** p<0.01; * p<0.05 compared with NT
@ p<0.05 compared with SD101
M1 MACROPHAGES
(11b+F4/80+CD38+,
n=3)
Fold change CD11b+F4/80+ over NT
*** p<0.001; ** p<0.01; * p<0.05 compared with NT
@ p<0.05 compared with SD101

FIGURE 3




FIGURE 4



PHASE 1B
COHORT A
DOSE ESCALATION 3 + 3 DESIGN AND
DOSE EXPANSION GROUP
COHORT B
DOSE RE-ESCALATION 3 + 3 DESIGN
Cohort A Objective: Identify the MTD of PEDD/HAI of SD-101
Cohort B Objective: Determine MTD of PEDD/HAI of SD-101 + pembrolizumab
B
SD-101 8 mg (n=3 – 6)
SD-101 4 mg (n=3 – 6)
Determine MTD from A
SD-101 at MTD -1 from A + pembrolizumab (n=3 – 6)
C
Determine MTD from B
DLT
No DLT
DOSE EXPANSION A (n = 10)
SD-101 at MTD -2 from A + pembrolizumab (n=3 – 6)
SD-101 at MTD from A + pembrolizumab (n=3 – 6)
Dose expansion with MTD
OPTIONAL DOSE EXPANSION B SD-101 + pembrolizumab (n=10)
PHASE 2
D
Two-cohort (HCC and ICC), open label phase, SD-101 PEDD/HAI in combination with CPI to assess co-primary endpoints of ORR and DOR

FIGURE 5A



COHORT C
DOSE RE-ESCALATION 3 + 3 DESIGN
B
Cohort C Objective: : Determine MTD of PEDD/HAI of SD-101 + nivolumab + ipilimumab
C
SD-101 at MTD-1 from B + nivolumab + ipilimumab (n=3-6)
DLT
No DLT
SD-101 at MTD-2 from B + nivolumab + ipilimumab (n=3- 6)
SD-101 at MTD from B + nivolumab + ipilimumab (n=3- 6)
OPTIONAL DOSE EXPANSION C (n=10)
D
SD-101 dose + single or dual CPI chosen from Cohort B or Cohort C

FIGURE 5B